Schlieren, Switzerland - March 12, 2013, Schlieren, Switzerland - Cytos Biotechnology, a biopharmaceutical company, announced the appointment of Matthias Alder as executive vice president for corporate development.
Article continues below
Mr. Alder has more than 19 years of of business, transactional and legal experience in the pharmaceutical and biotechnology industries. Most recently, he served as Senior Vice President Administration, General Counsel and Secretary of Micromet that was acquired by Amgen.
Prior to joining Micromet, he was a partner in the Life Sciences Transactions Practice at Cooley, and earlier in his career, he was in-house counsel at Ciba-Geigy and Novartis.
Mr. Alder holds law degrees from the University of Basel and the University of Miami (Florida), and is qualified to practice law in Switzerland and the United States.
The company also announed the appointment of Cheryl Lassen as VP for clinical development.
Ms. Lassen joins Cytos from Novartis where she was Program Leader for the global clinical development of the indacaterol program, a product since approved by the US FDA, EMA, Japan and many countries worldwide.
In her 20 year career, she has worked on a multitude of clinical development programs and in medical affairs in the United Kingdom and in South Africa for companies including Bristol Myers Squibb, Abbott Laboratories and Pharmacia.
Ms. Lassen received her Medical Degree from the University of the Witwatersrand in South Africa and holds a Science degree in microbiology and physiology from the University of South Africa.
The company also announced that Philipp Mueller, the current Executive Vice President Clinical Development will retire at the end of March 2013 and will continue to support the company as a consultant thereafter.
Mr. Mueller serves as Executive Vice President Clinical Development of Cytos since March 2003. He joined Cytos from Novartis Pharma AG, where he was Deputy Global Head Clinical Pharmacology. He has more than 20 years of clinical development experience with an emphasis on human pharmacology and clinical research to Cytos. ■